Sanofi (SNY)

NASDAQ: SNY · Real-Time Price · USD
51.98
-0.53 (-1.01%)
At close: May 23, 2025, 4:00 PM
51.29
-0.69 (-1.33%)
After-hours: May 23, 2025, 4:30 PM EDT
-1.01%
Market Cap 127.22B
Revenue (ttm) 48.82B
Net Income (ttm) 6.81B
Shares Out 1.23B
EPS (ttm) 5.45
PE Ratio 18.69
Forward PE 11.15
Dividend $2.21 (4.26%)
Ex-Dividend Date May 9, 2025
Volume 1,775,666
Open 51.86
Previous Close 52.51
Day's Range 51.80 - 52.37
52-Week Range 45.80 - 60.12
Beta 0.43
Analysts Buy
Price Target 62.50 (+20.24%)
Earnings Date Apr 24, 2025

About SNY

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. The company provides immunology and inflammation, rare diseases, neurology, oncology, and other medicines and vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines protecting against diphtheria, tetanus, pertussis, polio, Hib, and hepatitis B; inf... [Read more]

Sector Healthcare
Founded 1994
Employees 82,878
Stock Exchange NASDAQ
Ticker Symbol SNY
Full Company Profile

Financial Performance

In 2024, Sanofi's revenue was 44.29 billion, an increase of 7.73% compared to the previous year's 41.11 billion. Earnings were 5.56 billion, an increase of 2.96%.

Financial numbers in EUR Financial Statements

Analyst Forecast

According to 2 analysts, the average rating for SNY stock is "Buy." The 12-month stock price forecast is $62.5, which is an increase of 20.24% from the latest price.

Price Target
$62.5
(20.24% upside)
Analyst Consensus: Buy
Stock Forecasts

News

VIGIL NEUROSCIENCE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Vigil Neuroscience, Inc. - VIGL

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Vigil...

Other symbols: VIGL
2 days ago - Business Wire

Sanofi opens new, $130 million NJ offices in Morristown, showcasing innovative, modern design and strengthening US presence

MORRISTOWN, N.J. , May 22, 2025 /PRNewswire/ -- Sanofi today announces the formal opening of the company's new flagship US offices, unveiling a state-of-the-art modern workplace fostering collaboratio...

2 days ago - PRNewsWire

Sanofi to Buy Vigil Neuroscience for About $470 Million

Sanofi has entered an agreement to acquire Vigil Neuroscience for approximately $470 million, adding a new investigational treatment for Alzheimer's disease to the French pharmaceutical company's pipe...

Other symbols: VIGL
3 days ago - WSJ

Vigil Neuroscience Enters into Definitive Merger Agreement to be Acquired by Sanofi

- Vigil's shareholders to receive up to $10.00 per share in cash, comprised of $8.00 per share in cash at closing and a non-tradeable contingent value right of $2.00 per share in cash following the fi...

Other symbols: VIGL
3 days ago - GlobeNewsWire

Sanofi to acquire Vigil Neuroscience in $470 million deal

Sanofi said on Thursday that it would acquire Vigil Neuroscience, a clinical-stage biotech company, for $8 per share in cash, valuing the deal at about $470 million.

Other symbols: VIGL
3 days ago - Reuters

Press Release: Sanofi to acquire Vigil Neuroscience, Inc., adding a new investigational medicine to treat Alzheimer's disease to the neurology pipeline

Sanofi to acquire Vigil Neuroscience, Inc., adding a new investigational medicine to treat Alzheimer's disease to the neurology pipeline

Other symbols: VIGL
3 days ago - GlobeNewsWire

Viz.ai Announces Collaboration With Sanofi and Regeneron to Improve Management and Care of Chronic Obstructive Pulmonary Disease (COPD)

SAN FRANCISCO--(BUSINESS WIRE)-- #ai--Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced a multi-year partnership with Sanofi (NASDAQ: SNY), an innov...

Other symbols: REGN
4 days ago - Business Wire

French finance minister criticises Sanofi's $20 bln USA investment decision

France's finance minister criticised on Thursday a decision by French drugmaker Sanofi to invest at least $20 billion in the United States through to 2030, as France aims to get more companies investi...

9 days ago - Reuters

Sanofi To Navigate Tariff Impact With $20 Billion In Spending Through 2030

Sanofi SA SNY announced on Wednesday that it will invest at least $20 billion in the U.S. through 2030.

10 days ago - Benzinga

Sanofi to invest at least $20 billion in the US through 2030

French drugmaker Sanofi said on Wednesday it plans to invest at least $20 billion in the United States through 2030, which includes an increase in research and development spending and the allocation ...

10 days ago - Reuters

Hawaii in $700 million settlement with Bristol-Myers, Sanofi over Plavix warning label

Hawaii said on Friday it entered a $700 million settlement deal with pharmaceutical firm Bristol-Myers Squibb and units of French pharmaceutical company Sanofi in a case about warning labels related t...

Other symbols: BMY
15 days ago - Reuters

Pharma Worries Shift to Prices From Trade. Trump's Next Plan Could Sink Stocks.

The president says big news about drug pricing is coming next week.

Other symbols: JNJNVONVS
15 days ago - Barrons

Pressure is still on the pharma sector, says Mizuho's Jared Holz

Jared Holz, Mizuho, joins 'Fast Money' to talk headwinds to the pharma sector.

16 days ago - CNBC Television

Sanofi: Investing in prevention builds Europe's health and competitiveness

WARSAW, Poland, May 06, 2025 (GLOBE NEWSWIRE) -- As the Polish Presidency of the EU Council enters its final stage health policy remains central to Europe's strategic agenda. At the European Economic ...

18 days ago - GlobeNewsWire

Press Release: Annual General Meeting of April 30, 2025

Annual General Meeting of April 30, 2025 Approval of the financial statements for the fiscal year 2024 Distribution of a cash dividend of €3.92 per share, with payment as of May 14, 2025 Board composi...

24 days ago - GlobeNewsWire

Press Release: Sanofi and CD&R close Opella transaction, create global consumer healthcare leader

Sanofi and CD&R close Opella transaction, creat e global consumer healthcare leader Paris, April 30, 2025 . Opella today becomes an independent global leader in consumer healthcare, marking a pivotal ...

24 days ago - GlobeNewsWire

Press Release: When every second counts: Sanofi, McLaren Racing and United Autosports join forces to raise meningitis awareness at Le Mans 24 Hours race

When every second counts: Sanofi, McLaren Racing and United Autosports join forces to raise meningitis awareness at Le Mans 24 Hours race

25 days ago - GlobeNewsWire

Sanofi (SNY) Q1 2025 Earnings Call Transcript

Sanofi (NASDAQ:SNY) Q4 2024 Earnings Call Transcript Q1 2025 Earnings Conference Call April 25, 2025 7:00 AM ET Company Participants Thomas Kudsk Larsen - Head, Investor Relations Paul Hudson - Chief...

4 weeks ago - Seeking Alpha

Sanofi Sales, Profit Beat Expectations on Higher Demand for Skin, Asthma Drug

The pharmaceutical company said the profit was driven by a higher gross margin and slower operating expense growth.

4 weeks ago - WSJ

Sanofi's quarterly profit beats estimates on Dupixent boost, newer products

France's Sanofi reported first-quarter profit that beat analysts' expectations on Thursday, boosted by strong demand for its anti-inflammatory drug Dupixent, as well as newer treatments and vaccines.

4 weeks ago - Reuters

Press Release: Sanofi: strong Q1 performance and 2025 guidance confirmed

Sanofi: strong Q1 performance and 2025 guidance confirmed Paris, April 24, 2025 Q1 sales growth of 9.7% at CER 1 and business EPS 2 of €1.79 Pharma launches reached sales of €0.8 billion, up 43.8%, dr...

4 weeks ago - GlobeNewsWire

Novartis and Sanofi CEOs say EU should raise drug prices in face of tariffs

The European Union should allow drug prices to rise to U.S. levels in order to attract investment, the bosses of two European pharmaceutical giants said in a letter published in the Financial Times on...

Other symbols: NVS
4 weeks ago - Reuters

Sanofi-Regeneron's Dupixent gets FDA's nod for skin condition

The U.S. Food and Drug Administration approved the extended use of Sanofi and Regeneron's blockbuster drug Dupixent for patients with a type of skin condition, the two companies said on Friday.

Other symbols: REGN
5 weeks ago - Reuters

Press Release: Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria

Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria Approval based on phase 3 studies demonstrating Dupixent significantly reduced itch and...

Other symbols: REGN
5 weeks ago - GlobeNewsWire